Paridiprubart inhibits TLR4-dependant NF-κB activation by multiple pathogens
R. Malty, R. Hilbe, S. Ahn, L. Kesselman, J. Lam, K. Kasawara, L. Costa, N. Rajakulendran, B. Gordon, M. Brooks, S. Mubareka, I. Tancevski, S. D. Gray-Owen
This study shows that paridiprubart, a TLR4 inhibitor, suppresses NF-κB activation by multiple pathogens including SARS-CoV-2 and bacterial agents.
bioRxiv · Jun 27, 2023 · PreprintImmunology